Our Approach to a Diagnosis

The MNG neurobehavioral disorder portfolio encompasses a variety of rare genetic neurological disorders, including those related to cognition, neurodevelopment, and neurodegeneration. In many cases, neurobehavioral diseases can be categorized in multiple or all the sub-categories. Due to the complex and diverse presentation of these neurological diseases, our diagnostic approach is to offer both comprehensive panels with many clinically relevant genes as well as more focused panels designed around a well-characterized and distinct phenotype.


Neurobehavioral Disorder Tests We Offer

Intellectual Disability

Intellectual disability is a complex and genetically heterogeneous disorder characterized by significant limitations in both intellectual functioning and adaptive behavior. This generalized neurodevelopmental disorder can present as part of a syndrome or as an isolated phenomenon, and our next-generation sequencing (NGS) panel options offer a complete approach to a diagnosis. Our Comprehensive Intellectual Disability/Autism panel includes a significant number of genes known to cause both syndromic and nonsyndromic forms of intellectual disability. For patients with a clear syndromic or nonsyndromic phenotype, we also offer the Syndromic Intellectual Disability and Nonsyndromic Intellectual Disability panels. Finally, we also offer sequencing panels that target Macrocephaly and Overgrowth Syndromes, Microcephaly, and Hydrocephalus.

Intellectual Disability Panel Comparison

Company # of Genes # of Known Pathogenic Variants TAT Del/Dup Included STAT Available
901 20,883 14-28 Days
Fulgent 495 14,917 21-35 Days add on
Ambry 140 5,791 35-49 Days

Known pathogenic variants sourced from August 2017 ClinVar update. All information sourced from publicly posted data as of August 2017.

Dementia

Our approach to diagnosis in dementia follows a similar approach to intellectual disability. We offer a multi-faceted approach to the diagnosis of dementia disorders involving both NGS and repeat expansion testing when clinically relevant. Our Comprehensive Dementia panel has the option to include Huntington’s Disease (HTT) and Amyotrophic Lateral Sclerosis (C9orf72) repeat expansion testing. Additionally, we provide a more focused Alzheimer Disease and Frontotemporal Dementia panel with and without C9orf72 repeat expansion testing.

White Matter Disorders

For disorders affecting white matter, we offer the Comprehensive Leukodystrophy panel, which includes complimentary mitochondrial genome sequencing with deletion analysis. Panels focused on Vanishing White Matter disease, Non-Mitochondrial Leukodystrophy, and Mitochondrial Leukodystrophy are also available.

Explore Our Test Directory


Our Promise

MNG Laboratories is committed to a patient-centered testing menu, high-quality diagnostics, and first-in-class reporting driven by our Genome MaNaGer® analysis pipeline. Our Neurogenetic Answers™ reporting process helps us stay at the forefront of the evolving genetics field with our regularly-updated NGS panels. Our team-based approach to variant assessment ensures we provide you with the variants that cause or are likely to cause disease and keep the number of variants of unknown significance to a minimum. Our comprehensive approach to diagnostics is accompanied by a team of customer support and scientific personnel available to answer your questions regarding our process, technology, and reports.

Contact Us